is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor
• in combination with fulvestrant in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory
multiple myeloma who have received to three lines of therapy in combination with:
- Lenalidomide and dexamethasone; or
- Dexamethasone; or
- Daratumumab and dexamethasone; or
- Daratumumab and hyaluronidase-fihj and dexamethasone; or
- Isatuximab and dexamethasone.
Carfilzomib is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received or more lines of therapy.
Indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.
In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Palvicta may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.
In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Palvicta may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Gentamicin is an aminoglycoside antibiotic with broad spectrum bactericidal activity. It is indicated to treat severe infections caused by bacteria susceptible to BAGENTA such as, but not limited to:
• Urinary tract infections
• Respiratory tract infections
• Intra-abdominal infections
• CNS infections
• Severe neonatal infections
It is usually active against most strains of the following organisms: Escherichia coli, Klebsiella spp.,
Proteus spp. (indole positive and indole negative), Pseudomonas aeruginosa, Staphylococci, Enterobacter spp., Citrobacter spp. and Providencia spp. Consideration should be given to official local guidance on the appropriate use of antibacterial agents.
Powder and solvent for solution for injection
Biological Drug
NIMENRIX
Meningococcal group A, C, W-135 and Y conjugate vaccine 44,5,5,5,5 micrograms
Meningococcal group A, C, W-135 and Y conjugate vaccine 44,5,5,5,5 micrograms
الاستخدامات الطبية المعتمدة
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y.
